Aokage K, Koyama S, Kumagai S, Nomura K, et al. Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY). Clin Cancer Res 2024;30:5584-5592.
PMID: 39453771